Two year progression free survival in stage IV NSCLC patients treated with pemetrexed continuation maintenance

Category Primary study
JournalJournal of Clinical Oncology
Year 2016
This article has no abstract
Epistemonikos ID: d26e70527844de72578c25e8f62b7cbeec47f86e
First added on: Feb 07, 2025